Fosfomycin: Mechanism, Activity, Pharmacokinetics, and Clinical Use

Fosfomycin is a broad-spectrum antibiotic that kills bacteria by permanently disabling an enzyme they need to build their cell walls. Originally isolated from soil bacteria in the late 1960s, it has an unusually simple chemical structure and a mechanism of action shared by no other antibiotic in clinical use. That uniqueness has made fosfomycin increasingly valuable as resistance to more common antibiotics has climbed worldwide, particularly for urinary tract infections caused by multidrug-resistant organisms.

How Fosfomycin Destroys the Bacterial Cell Wall

Bacteria depend on a rigid outer structure called peptidoglycan to survive. Without it, the cell bursts under its own internal pressure. Building peptidoglycan requires a multi-step assembly line, and fosfomycin shuts down the very first committed step in that process. It does so by irreversibly binding to an enzyme called MurA (UDP-GlcNAc enolpyruvyl transferase), which catalyzes the reaction that kicks off peptidoglycan production.¹ Crystal structures show that fosfomycin forms a permanent covalent bond with a specific cysteine residue (Cys115) in MurA’s active site, locking the enzyme in a dead state.²

Because the bond is irreversible, the enzyme cannot recover. The bacterium has to manufacture entirely new MurA molecules to resume cell-wall construction. This is different from many antibiotics that temporarily sit on their target and can be displaced, which is part of why fosfomycin maintains activity even at relatively low concentrations. And because no other antibiotic class targets this same step, bacteria that are resistant to penicillins, cephalosporins, or carbapenems have no built-in cross-resistance to fosfomycin.

Getting Inside the Bacterium

An antibiotic that cannot enter its target cell is useless, and fosfomycin’s entry route is distinctive. Rather than passively diffusing through the bacterial membrane, fosfomycin hitches a ride on transport proteins that bacteria normally use to pull in nutrients. In E. coli, two main transporters carry fosfomycin into the cell: GlpT, which normally imports glycerol-3-phosphate, and UhpT, which normally imports glucose-6-phosphate.³ The drug essentially mimics these sugars well enough to get ferried across the membrane.

This has practical consequences. Under low-oxygen conditions, E. coli ramps up production of both GlpT and UhpT, which increases the amount of fosfomycin entering the cell and makes the bacteria more susceptible to the drug.⁴ This is relevant to deep-seated infections where oxygen levels are low, such as abscesses. On the flip side, bacteria that lose or mutate these transporters become resistant, a theme that runs through much of fosfomycin’s resistance story.

Not all species have both doors. Pseudomonas aeruginosa, a notoriously tough pathogen, relies solely on GlpT to import fosfomycin, lacking a functional UhpT equivalent.³ Having only one way in instead of two partly explains why Pseudomonas is inherently less susceptible to fosfomycin than E. coli.

Which Bacteria Fosfomycin Covers

Fosfomycin is active against a wide range of both Gram-positive and Gram-negative bacteria, though its potency varies considerably by species. The drug’s real strength lies against E. coli, the most common cause of urinary tract infections. Even among ESBL-producing E. coli strains (bacteria resistant to most penicillins and cephalosporins), fosfomycin remains highly active, with the concentrations needed to inhibit most isolates staying well within the treatable range.⁵ In one study of urinary tract isolates, about 99% of E. coli remained susceptible.⁶

Beyond E. coli, the picture gets more complicated. A systematic review of published susceptibility data found that Staphylococcus aureus, including MRSA strains, was generally susceptible, with frequency estimates around 90% or higher. Enterococci showed high susceptibility too, particularly E. faecalis (around 97%), though vancomycin-resistant E. faecium was less reliably covered.⁷ Fosfomycin is also frequently active against other resistant pathogens including vancomycin-resistant enterococci and multidrug-resistant Enterobacteriaceae.⁸

Klebsiella pneumoniae is a weak spot. Susceptibility rates are noticeably lower than for E. coli, and carbapenem-resistant strains of Klebsiella are particularly likely to also resist fosfomycin.⁷ Pseudomonas aeruginosa has intrinsically lower susceptibility, and Acinetobacter species are essentially resistant. One study of urinary isolates found Pseudomonas susceptibility around 66% for urinary specimens but only 32% for non-urinary sources, while Acinetobacter hovered near zero.⁶

Pharmacokinetics and How the Drug Is Given

Fosfomycin comes in oral and intravenous formulations, and they behave very differently in the body. The oral form, fosfomycin tromethamine, has modest bioavailability. Estimates generally fall in the range of 33% to 58%, depending on how the measurement is done.⁹ One pharmacokinetic study in healthy volunteers measured relative bioavailability at about 53%.¹⁰ That means roughly half the drug you swallow never reaches the bloodstream. What saves oral fosfomycin from irrelevance is that the kidneys excrete it unchanged into the urine, concentrating it precisely where it needs to act in a urinary tract infection. After an oral dose, about 37% of the drug winds up in the urine within 48 hours, with most of that appearing within the first 12 hours.¹⁰

Intravenous fosfomycin is a different story. Much higher doses can be delivered directly to the bloodstream, and the drug distributes well into tissues. Urinary recovery is substantially higher after IV dosing, with roughly 74% to 80% of the dose excreted unchanged in the urine by 48 hours.¹⁰ Fosfomycin is a small, water-soluble molecule that does not bind much to proteins in the blood, allowing it to penetrate into tissues that many larger antibiotics cannot reach easily. It crosses into cerebrospinal fluid at meaningful levels: in patients with brain infections receiving IV fosfomycin, the concentration in spinal fluid reached a median of about 46% of the blood concentration, which was enough to exceed the susceptibility breakpoint in 98% of measurements.¹¹

The drug shows concentration-dependent killing in urinary tract infection models, meaning that higher peak levels and overall drug exposure relative to the pathogen’s sensitivity drive better outcomes.¹² When given intravenously, continuous infusion keeps drug levels above the effective threshold for a longer portion of the dosing interval compared to giving the same total dose in intermittent boluses.¹³

Uncomplicated Urinary Tract Infections

The most established clinical use of fosfomycin is the single-dose oral treatment of uncomplicated lower urinary tract infections (cystitis) in women. A 3-gram sachet mixed with water, taken once, and the course is complete. Comparative trials going back decades have shown this single dose performs roughly as well as 7- to 10-day courses of standard agents like nitrofurantoin, norfloxacin, and trimethoprim-sulfamethoxazole for clinical cure.¹⁴ A recent meta-analysis confirmed that single-dose fosfomycin was comparable to other antibiotics for both clinical and microbiological resolution of uncomplicated UTIs with moderate certainty of evidence.¹⁵

That said, one well-designed randomized trial found that 5 days of nitrofurantoin outperformed single-dose fosfomycin. Clinical resolution by day 28 was achieved in 70% of women on nitrofurantoin versus 58% on fosfomycin, a 12-percentage-point gap that was statistically significant.¹⁶ The difference in microbiological clearance was similar. So fosfomycin works, but if maximizing cure rates is the priority and a multi-day regimen is acceptable, nitrofurantoin may hold an edge. Fosfomycin’s advantage is convenience and adherence: one dose, done, no chance of forgetting pills on day four.

Intravenous Fosfomycin for Serious Infections

Outside the world of simple bladder infections, intravenous fosfomycin plays an increasingly important role against severe or resistant infections, though its availability varies by country. In the United States, the IV formulation has had a complicated regulatory path, while in much of Europe and parts of Asia it has been used for decades. The FORTRESS study, a large real-world observational study, documented how IV fosfomycin is actually used in practice. The most common indications were bloodstream infections and sepsis (about 24% of cases), complicated urinary tract infections (18%), and bone and joint infections (17%). Other uses included hospital-acquired pneumonia, complicated skin infections, central nervous system infections, and infective endocarditis.¹⁷

In about a third of cases in that study, a multidrug-resistant pathogen was involved, and clinical success rates for infections caused by MDR or carbapenem-resistant organisms were around 78% to 82%.¹⁷ Case reports have illustrated its utility in extreme situations, such as treating a prostatic abscess caused by carbapenem-resistant E. coli that responded fully to fosfomycin monotherapy when other options were exhausted.¹⁸

Combination Therapy and Synergy

Fosfomycin is frequently used alongside other antibiotics rather than alone, especially for serious systemic infections. Its unique mechanism means it attacks a step in bacterial survival that other drugs leave untouched, creating opportunities for synergistic killing when combined. A review of published combination studies found that fosfomycin paired with various partners showed synergy against both Gram-positive and Gram-negative pathogens. Against MRSA, it worked synergistically with several cephalosporins, ciprofloxacin, imipenem, and rifampicin. Against Pseudomonas aeruginosa, synergy was observed with aminoglycosides like gentamicin and amikacin, as well as ceftazidime, cefepime, ciprofloxacin, levofloxacin, and aztreonam.¹⁹

The rationale for combination therapy is partly about synergy and partly about preventing resistance. When fosfomycin is used alone at sub-lethal concentrations, resistant mutants can emerge quickly because a single mutation in a transporter gene may be enough to block the drug’s entry. Adding a second antibiotic with a different mechanism makes it far harder for the bacterium to survive both simultaneously. This is why most infectious disease specialists avoid fosfomycin monotherapy for serious systemic infections, reserving the single-agent approach mainly for uncomplicated UTIs where drug concentrations in the urine far exceed what is needed.

How Bacteria Resist Fosfomycin

Resistance to fosfomycin develops through three main routes: the bacterium stops importing the drug, it modifies the target enzyme so fosfomycin can no longer bind, or it produces enzymes that chemically inactivate the drug.²⁰

The most common mechanism in clinical E. coli isolates involves mutations or deletions in the genes encoding those GlpT and UhpT transporters discussed earlier. In a Canadian surveillance study spanning 15 years, transport gene defects were found in about 63% of fosfomycin-resistant E. coli isolates that lacked other known resistance genes, and none of the susceptible isolates had these mutations.²¹ In MRSA, a similar pattern holds: roughly 90% of fosfomycin-resistant strains carried mutations in the transporter genes, and strains with defects in both transporters showed extremely high resistance levels.²²

The other major concern is a family of enzymes called FosA, FosB, and FosX that can chemically modify fosfomycin and render it inactive. The gene fosA3 is particularly worrisome because it sits on plasmids, which are small circular DNA molecules that bacteria share with each other, sometimes across species. Carbapenem-resistant Klebsiella pneumoniae isolates, for instance, can carry fosA3 alongside their other resistance genes.²³ When a resistance gene travels on a plasmid, it can spread much faster than if it required each bacterium to independently evolve the same mutation.

Activity Against Biofilms

Many chronic and device-related infections involve biofilms, communities of bacteria encased in a protective matrix that makes them dramatically harder to kill with standard antibiotics. Fosfomycin has shown the ability to degrade existing biofilms produced by multidrug-resistant urinary E. coli. In laboratory studies, the drug broke down biofilms across a range of concentrations, with weaker biofilm producers requiring less fosfomycin than moderate or strong producers.²⁴ Other research has confirmed that fosfomycin can significantly reduce E. coli biofilms, though it does not appear effective against bacteria that have invaded inside host cells.²⁵

Against Pseudomonas biofilms, fosfomycin alone has limited intrinsic activity, but combining it with aminoglycosides appears to improve penetration and killing within the biofilm structure.²⁶ This has relevance for chronic infections like those associated with orthopedic implants, urinary catheters, and prosthetic heart valves.

Safety and Side Effects

Oral fosfomycin is well tolerated for its intended one-dose use. The most common side effects are gastrointestinal: nausea, diarrhea, and stomach discomfort, usually mild and self-limiting.²⁷ The oral form is categorized as pregnancy category B, meaning animal studies have not shown fetal harm and it can be considered when the benefits outweigh theoretical risks, making it one of the few antibiotic options for UTIs during pregnancy when first-line agents cannot be used.

Intravenous fosfomycin carries a distinct safety concern that clinicians need to watch for. Each gram of the IV formulation contains about 14.4 milliequivalents (330 milligrams) of sodium. Since typical IV dosing runs around 12 grams per day, the sodium load is substantial, potentially pushing patients with heart failure or kidney disease into fluid overload.²⁷ Other reported side effects from IV use include rash, inflammation at the injection site, low potassium levels, and digestive symptoms. Routine monitoring of electrolytes and fluid balance is standard practice when the IV form is used for multi-day courses.

The Lab Testing Problem

One of fosfomycin’s practical headaches has nothing to do with the drug itself and everything to do with testing whether a given bacterium is susceptible. The reference method for determining fosfomycin susceptibility is agar dilution, a manual, labor-intensive technique that most routine microbiology labs do not perform. More convenient methods like gradient diffusion strips and automated broth microdilution panels exist, but their accuracy varies by organism.

For E. coli, disk diffusion testing agrees well with the reference method, hitting 100% agreement in one study.²⁸ For Klebsiella pneumoniae, however, gradient strips and disk diffusion perform poorly, with one study reporting categorical agreement as low as 46% depending on the breakpoint system used.²⁸ For Pseudomonas, the situation is similarly messy: different testing methods yielded susceptibility rates ranging from 49% to 86% for the same collection of isolates, depending on which technique was used.²⁹ A lab report saying a Klebsiella or Pseudomonas isolate is susceptible to fosfomycin may or may not be accurate, depending on how the test was performed. Clinicians treating serious infections with fosfomycin against these organisms should ideally know which testing method was used.

Fosfomycin Resistance in the Food Chain

Fosfomycin has been used in veterinary medicine, particularly in livestock production in parts of Asia, and this use has consequences beyond the farm. Fosfomycin resistance genes, especially the plasmid-borne fosA3 gene, have been detected in bacteria isolated from pigs, chickens, pigeons, cows, and even vegetables.³⁰ Because these genes sit on mobile genetic elements, they can transfer from animal-associated bacteria to human pathogens. The detection of fosA3 in E. coli from food animals has raised concerns about resistance moving through the food chain and undermining the drug’s usefulness in human medicine.³¹

The application of animal manure as fertilizer further extends the reach of these resistance genes into soil and water. This agricultural dimension of antibiotic resistance is not unique to fosfomycin, but it is particularly concerning for a drug that is valued precisely because it remains effective against organisms resistant to most other antibiotics. If fosfomycin resistance becomes widespread through agricultural transmission, one of the last-resort options for multidrug-resistant infections would be weakened.

Immunomodulatory Effects Beyond Killing Bacteria

An emerging area of interest is fosfomycin’s effects on the immune system itself. Preclinical research suggests that the drug does more than just kill bacteria: it damps down excessive inflammation. Studies have found that fosfomycin suppresses key inflammatory signaling molecules including TNF-α, IL-1β, and IL-6, while boosting the anti-inflammatory mediator IL-10. It also appears to reduce the activation of major inflammatory pathways in cells, limit the migration of infection-fighting neutrophils, and decrease the proliferation of T-cells and B-cells.³²

Animal experiments have supported these observations. In a rat model of acute inflammation, fosfomycin treatment significantly reduced the volume and protein content of inflammatory fluid, lowered inflammatory cell counts, and suppressed production of inflammatory mediators at both the protein and gene level.³³ Whether these immune-modulating effects translate into meaningful clinical benefits in humans, beyond the drug’s direct antibacterial action, is still an open question. But the potential is intriguing: in severe infections where the body’s own inflammatory response causes tissue damage (sepsis being the extreme example), an antibiotic that simultaneously kills the pathogen and tones down harmful inflammation could be a genuine advantage. The research here is still largely preclinical, so this remains a “watch this space” area rather than a clinical selling point.